We are looking for volunteers to join our study. We want to see if a medicine called itraconazole can help stop a condition called Barrett's Esophagus (BE) from coming back after treatment. This study will help us learn if itraconazole is safe and how it works compared to a pretend pill with no medicine, called a placebo. If you join, you will get either itraconazole or the placebo. Your participation will help us understand more about keeping BE from returning.

Have you had an alcoholic drink today or in the past 4 months? Have you been diagnosed with alcohol-related liver disease (ALD)? You may be able to participate in a research study that is exploring a medication that may help reduce the effects of ALD. Compensation provided.

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with Compensated Cirrhosis due to NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

The purpose of this study is to compare the effects of the research medicine, solrikitug, with a placebo to find out which is better for treating eosinophilic esophagitis (EoE) in adult patients. The purpose is to see if the research medicine helps improve EoE symptoms: dysphagia (difficulty swallowing), tissue inflammation, clinical symptoms and quality of life.

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

Do you have Alpha-Gal Allergy AND GI symptoms such as abdominal pain, vomiting, and diarrhea? Have you experienced improvement of these symptoms on a mammalian meat-free diet? You may be eligible for our study to help UNC researchers better understand alpha-gal allergy with belly/gastrointestinal symptoms. Compensation provided.

Are you 16 years and older, have Eosinophilic Esophagitis, have tried other therapies but they have not worked, and you have had multiple dilations for narrowing in your throat in the past 12 months? If you meet these criteria then you may be eligible for a study investigating the use of dupilumab to treat EoE patients with severe strictures. Compensation provided.

People with Barrett's esophagus are at higher than average risk of developing esophageal cancer. Obeticholic Acid (OCA) is a medication similar to bile acids (a fluid made and released by the liver). OCA binds to a group of cells in the intestine that is believed to have a positive effect on preventing cancer development. The purpose of this study is to compare the safety and effects of OCA with that of a placebo on the risk of developing esophageal cancer in people with Barrett's esophagus.

We have study goals: (1) To conduct phone interviews to ask about symptoms and life impact from adult patients living with PSC; (2) To lead community advisory board discussions to decide on using existing symptom measures 'as is', modify existing measures or develop new measures to evaluate PSC symptoms; and (3) To conduct interviews with adult patients with PSC to assess their understanding and comprehension of selected symptom measures. We plan to consent and enroll up to 75 patients into a Screening database. From the database, we will select up to 24 patients to interview for Aim 1 and up to 16 patients to interview for Aim 3. Interviews will be conducted over the phone by staff at Duke University. At the end of the study, we will have 3 PSC symptom measures for use in future PSC studies.

Have you been diagnosed with Eosinophilic Esophagitis (EoE) and therapies you've tried don't work, or you aren't interested in taking drugs to treat your EoE? Are you willing to modify your diet to exclude certain foods for 8 weeks? If so, then you may be eligible to participate in a study to see if an individualized diet elimination therapy works to treat EoE.